{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-161170","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.313661+00:00","generated_at":"2026-06-01T04:24:03.262263+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Disc Medicine reports positive Phase 2 data for bitopertin in EPP and updates for DISC-0974 and DISC-3405 at EHA 2024","bullets":["Bitopertin reduced protoporphyrin IX by 40% in 60 mg group and cut phototoxic reactions by 75.3% (p=0.011) in AURORA trial.","DISC-0974 showed 68.9% of non-transfusion dependent myelofibrosis patients had hemoglobin response ≥1.5 g/dL; one TD patient became transfusion independent.","DISC-3405 demonstrated >50% mean serum iron reduction sustained for at least 4 weeks at 300 mg dose in healthy volunteers.","No serious adverse events reported across all three programs to date.","Data were presented at European Hematology Association 2024 Congress on June 14, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-161170","json":"https://secwatch.observer/filing/0001193125-24-161170.json","markdown":"https://secwatch.observer/filing/0001193125-24-161170.md","text":"https://secwatch.observer/filing/0001193125-24-161170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524161170/0001193125-24-161170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524161170/d826950d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:24:03.262263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}